GT Biopharma (NASDAQ:GTBP) Coverage Initiated at Roth Mkm

Research analysts at Roth Mkm initiated coverage on shares of GT Biopharma (NASDAQ:GTBP) in a note issued to investors on Monday,Benzinga reports. The firm set a “buy” rating and a $11.00 price target on the stock. Roth Mkm’s price objective would suggest a potential upside of 292.86% from the company’s current price.

GT Biopharma Price Performance

Shares of NASDAQ:GTBP opened at $2.80 on Monday. GT Biopharma has a 12 month low of $1.92 and a 12 month high of $10.66. The stock’s 50 day moving average price is $2.64 and its 200 day moving average price is $2.74.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.